v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

IMPACT OF GLIMEPIRIDE AND SITAGLIPTIN ON C-REACTIVE PROTEIN IN OVERWEIGHT PATIENTS SUFFERING FROM TYPE-2 DIABETES

AUTHORS:

Dr Saneela Mussawar, Dr Muhammad Akhtar, Dr Hina Zahida

ABSTRACT:

Objectives: The purpose of this research work was to provide the comparison of anti-inflammatory impact of glimepiride and sitagliptin by calculating the C - reactive protein (CRP) in the overweight patients suffering from type-2 diabetic. Methodology: This research work was carried out at Sheikh Zayed Hospital Rahim Yar khan from March to September 2020. A sum of 110 overweight patients suffering from type-2 diabetes were separated into 2 groups. We gave tablet sitagliptin 50.0mg to the patients of Group-A whereas the patients of Group-B received the tablet of glimepiride 2.0mg for a period of complete 12 weeks. We titrated the dose according to the level of blood sugar. Primary outcome was the measurement of the alterations in the CRP whereas secondary outcomes were the alterations in the body mass index, level of blood sugar, level of HbA1c, profile of lipids and CRP from the baseline in both groups with the utilization of SPSS V.20. Results: After completion of 12 weeks of treatment, there was an increase in body weight of the patients of glimepiride group but there was slightly reduction in the patients of sitagliptin group, however the difference was not significant statistically (P=0.070). Although, patients of both groups were present with decrease in the levels of HbA1c and blood sugar but this difference was also insignificant (P=0.590 and P=0.170 respectively). However, there was an improvement in the lipid profile much significantly in the patients of sitagliptin as compared to the patients of glimepiride group as TC (Total Cholesterol) (-25.0±32.50 vs +1.50±45.40 P=0.020), TG (Triglycerides) (-19.0±44.60 vs -1.80±48.70 P=0.0010), LDL- cholesterol (-10.0±22.40 vs -0.80±18.70 P=0.0010) and HDL-cholesterol (-2.60±6.20 vs 1.20±5.20 P=0.030). Sitagliptin decreased the CRP significantly as compared to glimepiride (-2.30±1.80 vs 0.80±1.50 P=0.0010). Conclusion: There was strong anti-inflammatory impact of sitagliptin marked by the decrease in the level of CRP as compared to glimepiride in the overweight patients of type-2 diabetes. It also had the advantageous impacts on the glycemic as well as lipid profiles. Keywords: Anti-Inflammatory, Type-2 Diabetes, Lipid, C - Reactive Protein, Glimepiride, Sitagliptin.

FULL TEXT

<
Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.